rabeprazole sodium

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heartburn

Conditions

Heartburn

Trial Timeline

Oct 1, 2005 → Jun 1, 2008

NCT ID

NCT00236184

About rabeprazole sodium

rabeprazole sodium is a phase 3 stage product being developed by Eisai for Heartburn. The current trial status is completed. This product is registered under clinical trial identifier NCT00236184. Target conditions include Heartburn.

What happened to similar drugs?

7 of 14 similar drugs in Heartburn were approved

Approved (7) Terminated (0) Active (7)

✅esomeprazole 40 mgAstraZenecaApproved

✅Esomeprazole magnesium (Nexium)AstraZenecaApproved

✅Esomeprazole + Lansoprazole + PantoprazoleAstraZenecaApproved

✅Esomeprazole Magnesium + LansoprazoleAstraZenecaApproved

✅Esomeprazole 20 mg + PlaceboPfizerApproved

✅Talcid (Hydrotalcite, BAY4516H) + Famotidine + PlaceboBayerApproved

✅Omeprazole 20 mg + Sodium Bicarbonate 1100 mg + Omeprazole 20 mgBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01264822	Pre-clinical	Completed	Jan 13, 2011	Nov 17, 2016	Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
NCT01321567	Pre-clinical	Completed	Jan 1, 2011	Aug 1, 2013	Refractory Reflux Esophagitis
NCT00855361	Phase 1	Completed	Jul 1, 2009	Dec 1, 2011	Gastroesophageal Reflux
NCT00747695	Phase 1	Completed	Mar 1, 2008	Sep 1, 2009	GERD
NCT01286194	Pre-clinical	Completed	Apr 1, 2006	Jan 1, 2007	Frequent Heartburn
NCT00236184	Phase 3	Completed	Oct 1, 2005	Jun 1, 2008	Heartburn
NCT00132496	Phase 2	Completed	Aug 1, 2005	Jul 1, 2006	Gastroesophageal Reflux Disease

Competing Products

20 competing products in Heartburn

See all competitors

Product	Company	Stage	Hype Score
rabeprazole sodium + placebo	Eisai	Phase 3	40
Rabeprazole sodium	Eisai	Pre-clinical	26
famotidine (+) calcium carbonate (+) magnesium hydroxide tablet + Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water + Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water	Johnson & Johnson	Phase 1	29
esomeprazole 40 mg	AstraZeneca	Approved	43
Esomeprazole magnesium (Nexium)	AstraZeneca	Approved	43
Esomeprazole	AstraZeneca	Phase 3	40
Esomeprazole	AstraZeneca	Phase 3	40
Esomeprazole + Lansoprazole + Pantoprazole	AstraZeneca	Approved	43
Esomeprazole Magnesium + Lansoprazole	AstraZeneca	Approved	43
Famotidine FCT + Famotidine CT	Merck	Phase 1	29
Lanzoprazole	Novartis	Phase 3	40
Lansoprazole + Lansoprazole + placebo	Novartis	Phase 3	40
Lansoprazole	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg + Lansoprazole + Calcium carbonate/magnesium hydroxide + Placebo	Novartis	Phase 2	35
Esomeprazole 20 mg + Placebo	Pfizer	Approved	43
bi-layer calcium carbonate tablet (BAY1180654) + Immediate release calcium carbonate tablet (BAY1180654)	Bayer	Phase 1	26
omeprazole/sodium bicarbonate + omeprazole magnesium	Bayer	Phase 1	26
Talcid (Hydrotalcite, BAY4516H) + Famotidine + Placebo	Bayer	Approved	40
Omeprazole 20 mg + Sodium Bicarbonate 1100 mg + Omeprazole 20 mg	Bayer	Approved	40